Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Stock Short Interest Rises 61.6%

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 159,295 shares, an increase of 61.6% from the September 30th total of 98,600 shares. Based on an average daily volume of 3,958,965 shares, the short-interest ratio is presently 0.0 days. Approximately 1.0% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Tuesday, September 22nd. Finally, Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4,800.00.

Institutional Investors Weigh In On Enlivex Therapeutics

A number of hedge funds have recently bought and sold shares of ENLV. Susquehanna International Group LLP increased its stake in shares of Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after purchasing an additional 147,334 shares during the period. WINTON GROUP Ltd bought a new stake in Enlivex Therapeutics during the 2nd quarter valued at approximately $55,000. Finally, Bank of America Corp DE boosted its stake in Enlivex Therapeutics by 53.2% during the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after purchasing an additional 45,303 shares during the period. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Trading Up 10.9%

NASDAQ:ENLV opened at $1.56 on Tuesday. Enlivex Therapeutics has a 1 year low of $1.40 and a 1 year high of $434.40. The firm’s fifty day simple moving average is $10.12 and its 200 day simple moving average is $138.47. The firm has a market capitalization of $1.70 million, a PE ratio of -0.01 and a beta of 1.42.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression.

Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.